These findings position the STEAP4+ myoCAF‐TFE3/tumor‐HIF1A axis as a master regulator of anti‐androgen resistance, offering clinically actionable targets to extend treatment efficacy in advanced prostate cancer. This evidence concerns the gene STEAP4 and prostate carcinoma.